After 10 years of R&D, SEPARATIVE’s process replaces the conventional silica column with a micronichoneycomb-structured material to achieve unparalleled performance. Separative has entered in the process automation and control phase. We will explain in this document the progresses made in order to meet the pharmaceutical standards and specifications for a column with 43μm capillaries. We will detail the different tests performed in order to validate that our columns meet the pharmaceutical manufacturing requirements. Our chromatography column, SEP43, is the first to meet the industry need to purify molecules to high purity quickly and at low pressure. Purification is key for all chemical industries and more especially for the pharmaceutical industry. Yet, current techniques are often expensive, slow, energy intensive, and create issues for health, safety and the environment. Hence, purification has become a lock in drug discovery. SEP43 would enable faster drug and chemical development, at lower cost, with a safer and more eco-friendly manufacturing process. On the industrial standpoint, Separative has develop its pilot line specifications, has looked for potential partners/consultants/sub-contractors has validated their technical choices, asked for quotations and has on the automation part passed orders.